The FDA last week cleared Ascendis Pharma’s Skytrofa, a long-acting growth hormone, for the treatment of growth hormone deficiency (GHD) in patients weighing at least 25.4 pounds. Skytrofa is Acendis’ first FDA-approved drug, and is also the first once-weekly childhood GHD treatment. Novo Nordisk’s Norditropin is one of the most advantaged GHD therapies, holding preferred status under the pharmacy benefit for 12.8% of all covered lives, and growing to 45.0% with utilization management restrictions applied. Pfizer is also working on a once-weekly childhood GHD drug, with an FDA decision set for October.
SOURCE: MMIT Analytics, as of 8/30/21